---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-23-021408"
form_type: "8-K"
ticker: "BJDX"
cik: "0001704287"
company_name: "Bluejay Diagnostics, Inc."
filed_at: "2023-03-20T23:59:59+00:00"
generated_at: "2026-06-17T23:00:57.676467+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Bluejay Diagnostics reports 2022 net loss $9.3M; FDA submission delayed to H1 2024

## Summary
- Net loss $9.3M ($0.46 per share) vs $3.5M ($0.41 per share) in 2021.
- Cash and cash equivalents $10.1M, down from $19.0M year-over-year.
- R&D expense increased 262% to support clinical trials for planned FDA submission.
- FDA feedback requires expanded clinical study; de novo submission timeline pushed to H1 2024.
- Company to require additional funding to reach commercialization due to delay.

## SEC filing metadata
- accession: 0001213900-23-021408
- form_type: 8-K
- ticker: BJDX
- cik: 0001704287
- company_name: Bluejay Diagnostics, Inc.
- filed_at: 2023-03-20T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1704287/000121390023021408/0001213900-23-021408-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1704287/000121390023021408/ea175516-8k_bluejay.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-23-021408
- JSON: https://secwatch.observer/filing/0001213900-23-021408.json
- Plain text: https://secwatch.observer/filing/0001213900-23-021408.txt

## Key facts
- Earnings Releases
  Bluejay Diagnostics, Inc. reported the year ended December 31, 2022 results: net income $9.3 million, or $0.46 per share, EPS $0.46 per share.
  - Period: the year ended December 31, 2022
  - Net income: $9.3 million, or $0.46 per share
  - EPS: $0.46 per share
  - Result: reported results
  source text: Bluejay Diagnostics Reports 2022 Financial Results
  evidence_url: https://www.sec.gov/Archives/edgar/data/1704287/000121390023021408/0001213900-23-021408-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.